Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Aug;32(8):1137–1142. doi: 10.1128/aac.32.8.1137

Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.

G Abele 1, B Eriksson 1, J Harmenberg 1, B Wahren 1
PMCID: PMC172365  PMID: 2847643

Abstract

The triphosphates of the antiherpesvirus acyclic guanosine analogs 9-[4-hydroxy-2(hydroxymethyl)butyl] guanine (2HM-HBG), 9-(2-hydroxyethoxymethyl)guanine (acyclovir [ACV]), and 9-(3,4-dihydroxybutyl)guanine (buciclovir) were examined for their effects on partially purified varicella-zoster virus (VZV) DNA polymerase as well as cellular DNA polymerase alpha. The triphosphate of 2HM-HBG competitively inhibited the incorporation of dGMP into DNA catalyzed by the VZV DNA polymerase. 2HM-HBG-triphosphate (2HM-HBG-TP) had a higher affinity for the dGTP-binding site on the VZV DNA polymerase than did dGTP; apparent Km and Ki values of dGTP and 2HM-HBG-TP were 0.64 and 0.034 microM, respectively. ACV-triphosphate (ACV-TP) was found to be the most potent inhibitor of VZV DNA polymerase. ACV-TP had a 14 and 464 times better direct inhibitory effect than 2HM-HBG-TP and buciclovir-triphosphate, respectively. The cellular (human embryonic lung fibroblast) DNA polymerase alpha inhibition was related to viral polymerase inhibition as efficacy ratios: 2HM-HBG-TP had a ratio of more than 1,000, which appeared to be similar to that of ACV-TP.

Full text

PDF
1137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abele G., Karlström A., Harmenberg J., Shigeta S., Larsson A., Lindborg B., Wahren B. Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother. 1987 Jan;31(1):76–80. doi: 10.1128/aac.31.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheng Y. C., Ostrander M. Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization. J Biol Chem. 1976 May 10;251(9):2605–2610. [PubMed] [Google Scholar]
  4. Coen D. M., Schaffer P. A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2265–2269. doi: 10.1073/pnas.77.4.2265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DUBBS D. R., KIT S. MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY. Virology. 1964 Apr;22:493–502. doi: 10.1016/0042-6822(64)90070-4. [DOI] [PubMed] [Google Scholar]
  6. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  7. Eriksson B., Larsson A., Helgstrand E., Johansson N. G., Oberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta. 1980 Mar 28;607(1):53–64. doi: 10.1016/0005-2787(80)90220-8. [DOI] [PubMed] [Google Scholar]
  8. Furman P. A., Coen D. M., St Clair M. H., Schaffer P. A. Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. J Virol. 1981 Dec;40(3):936–941. doi: 10.1128/jvi.40.3.936-941.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978 Dec 25;253(24):8721–8727. [PubMed] [Google Scholar]
  10. Juel-Jensen B. E., MacCallum F. O., Mackenzie A. M., Pike M. C. Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials. Br Med J. 1970 Dec 26;4(5738):776–780. doi: 10.1136/bmj.4.5738.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Juel-Jensen B. Severe chickenpox and purpura fulminans in zoster treated with vidarabine. J Antimicrob Chemother. 1976 Sep;2(3):261–264. doi: 10.1093/jac/2.3.261. [DOI] [PubMed] [Google Scholar]
  12. Karlström A. R., Källander C. F., Abele G., Larsson A. Acyclic guanosine analogs as substrates for varicella-zoster virus thymidine kinase. Antimicrob Agents Chemother. 1986 Jan;29(1):171–174. doi: 10.1128/aac.29.1.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Larsson A., Stenberg K., Ericson A. C., Haglund U., Yisak W. A., Johansson N. G., Oberg B., Datema R. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother. 1986 Oct;30(4):598–605. doi: 10.1128/aac.30.4.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mar E. C., Cheng Y. C., Huang E. S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983 Oct;24(4):518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mar E. C., Huang Y. S., Huang E. S. Purification and characterization of varicella-zoster virus-induced DNA polymerase. J Virol. 1978 May;26(2):249–256. doi: 10.1128/jvi.26.2.249-256.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Miller R. L., Rapp F. Varicella-zoster virus-induced DNA polymerase. J Gen Virol. 1977 Sep;36(3):515–524. doi: 10.1099/0022-1317-36-3-515. [DOI] [PubMed] [Google Scholar]
  17. Peterslund N. A., Seyer-Hansen K., Ipsen J., Esmann V., Schonheyder H., Juhl H. Acyclovir in herpes zoster. Lancet. 1981 Oct 17;2(8251):827–830. doi: 10.1016/s0140-6736(81)91102-8. [DOI] [PubMed] [Google Scholar]
  18. Sakuma T. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Antimicrob Agents Chemother. 1984 Jun;25(6):742–746. doi: 10.1128/aac.25.6.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schlabach A., Fridlender B., Bolden A., Weissbach A. DNA-dependent DNA polymerases from HeLa cell nuclei. II. Template and substrate utilization. Biochem Biophys Res Commun. 1971 Aug 20;44(4):879–885. doi: 10.1016/0006-291x(71)90793-5. [DOI] [PubMed] [Google Scholar]
  20. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Selby P. J., Powles R. L., Janeson B., Kay H. E., Watson J. G., Thornton R., Morgenstern G., Clink H. M., McElwain T. J., Prentice H. G. Parenteral acyclovir therapy for herpesvirus infections in man. Lancet. 1979 Dec 15;2(8155):1267–1270. doi: 10.1016/s0140-6736(79)92281-5. [DOI] [PubMed] [Google Scholar]
  22. Shigeta S., Mori S., Yokota T., Konno K., De Clercq E. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity. Antimicrob Agents Chemother. 1986 Jun;29(6):1053–1058. doi: 10.1128/aac.29.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shigeta S., Yokota T., Iwabuchi T., Baba M., Konno K., Ogata M., De Clercq E. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis. 1983 Mar;147(3):576–584. doi: 10.1093/infdis/147.3.576. [DOI] [PubMed] [Google Scholar]
  24. Shiraki K., Ogino T., Yamanishi K., Takahashi M. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine. Biken J. 1983 Mar;26(1):17–23. [PubMed] [Google Scholar]
  25. Shiraki K., Ogino T., Yamanishi K., Takahashi M. Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus. Biken J. 1986 Mar;29(1):7–10. [PubMed] [Google Scholar]
  26. Stenberg K., Larsson A., Datema R. Metabolism and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in herpes simplex virus-infected vero cells. J Biol Chem. 1986 Feb 15;261(5):2134–2139. [PubMed] [Google Scholar]
  27. Sundqvist V. A., Wahren B. Development of sensitive and enzyme-linked immunoassays for herpesvirus antigens and some applications. Dev Biol Stand. 1982;52:245–253. [PubMed] [Google Scholar]
  28. Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]
  29. Yokota T., Ogata M., Shigeta S. A mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity. Fukushima J Med Sci. 1983 Jul;29(3-4):101–111. [PubMed] [Google Scholar]
  30. de Clercq E., Degreef H., Wildiers J., de Jonge G., Drochmans A., Descamps J., de Somer P. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster. Br Med J. 1980 Nov 1;281(6249):1178–1178. doi: 10.1136/bmj.281.6249.1178. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES